Fentanyl iontophoretic - ALZA Corporation

Drug Profile

Fentanyl iontophoretic - ALZA Corporation

Alternative Names: E-TRANS fentanyl; Fentanyl HCI; Fentanyl iontophoretic transdermal system; Fentanyl transdermal - ALZA Corporation; IONSYS; SyB P 1501

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation
  • Developer The Medicines Company
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Postoperative pain

Most Recent Events

  • 09 Feb 2018 SymBio Pharmaceuticals terminates a phase III trial for Postoperative pain due to the announcement for completion of the termination of development of SyB P-1501 in Japan (Transdermal) (NCT03005899)
  • 09 Feb 2018 Discontinued - Phase-III for Postoperative pain in Japan (Transdermal)
  • 30 Nov 2017 The Medicines Company terminates its license with SymBio Pharmaceuticals for Fentanyl iontophoretic in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top